Mtech's Mission

    The mission of the Maryland Technology Enterprise Institute (Mtech), a unit of the A. James Clark School of Engineering at the University of Maryland, is to:

    • Educate the next generation of technology entrepreneurs;
    • Create successful technology ventures; and
    • Connect Maryland companies with university resources to help them succeed.

    Mtech has built a comprehensive entrepreneurship and innovation ecosystem at the University of Maryland. Its programs arm top students from around the world with the knowledge of how to successfully launch companies and guide aspiring and existing entrepreneurs through the entire lifecycle of launching and maintaining technology-based ventures.

    Read more about Mtech >

    < MTECH


    ASPIRE is a grant program for undergraduate researchers working with Clark School faculty on projects with commercial potential


    TAP Graduate Digene Acquired for $1.6 Billion

    TAP Graduate Digene Acquired for $1.6 Billion

    Digene Corporation, a graduate of the Technology Advancement Program (TAP), announced a deal on June 3 to be acquired by Netherlands-based Qiagen NV, a maker of genetic testing equipment, for $1.6 billion.

    Digene was a portfolio company in TAP from 1985 to 1988.

    The announced transaction, subject to the tender of a majority of Digene's common stock and approval of Qiagen's shareholders, as well as regulatory approvals, is expected to close in September.

    Through the deal, Digene shareholders can elect to receive 3.545 shares of Qiagen stock for each Digene share owned, or $61.25 a share in cash. That share value represents a 37 percent premium to its closing price on the Nasdaq on Friday, June 1, the companies indicated in a joint statement.

    Digene and Qiagen forecast that the combined company will have over $350 million in molecular diagnostics revenues, and more than $800 million in revenues overall in 2008.

    Digene is a leader in molecular diagnostics. The company’s primary product, the Digene HPV (human papillomavirus) Test, screens for the presence of high-risk types of the virus that have been shown to be the cause of cervical cancer. The Digene HPV Test is the only test for HPV that is both FDA-approved and CE-marked (approved in Europe). This addresses one of the largest and most rapidly expanding market segments in women's health and molecular diagnostics.

    Read Digene's official press release.

    June 4, 2007

    Prev   Next